HIF-1α Pathway in COVID-19: A Scoping Review of Its Modulation and Related Treatments

Página do item simplificado
dc.contributor.authorda Silva F.P.G.
dc.contributor.authorMatte R.
dc.contributor.authorWiedmer D.B.
dc.contributor.authorda Silva A.P.G.
dc.contributor.authorMenin R.M.
dc.contributor.authorBarbosa F.B.
dc.contributor.authorMeneguzzi T.A.M.
dc.contributor.authorPereira S.B.
dc.contributor.authorFausto A.T.
dc.contributor.authorKlug L.
dc.contributor.authorMelim B.P.
dc.contributor.authorBeltrao C.J.
dc.date.accessioned2025-06-01T06:12:23Z
dc.date.available2025-06-01T06:12:23Z
dc.date.issued2025
dc.description.abstract© 2025 by the authors.The COVID-19 pandemic, driven by SARS-CoV-2, has led to a global health crisis, highlighting the virus’s unique molecular mechanisms that distinguish it from other respiratory pathogens. It is known that the Hypoxia-Inducible Factor 1α (HIF-1α) activates a complex network of intracellular signaling pathways regulating cellular energy metabolism, angiogenesis, and cell survival, contributing to the wide range of clinical manifestations of COVID-19, including Post-Acute COVID-19 Syndrome (PACS). Emerging evidence suggests that dysregulation of HIF-1α is a key driver of systemic inflammation, silent hypoxia, and pathological tissue remodeling in both the acute and post-acute phases of the disease. This scoping review was conducted following PRISMA-ScR guidelines and registered in INPLASY. It involved a literature search in Scopus and PubMed, supplemented by manual reference screening, with study selection facilitated by Rayyan software. Our analysis clarifies the dual role of HIF-1α, which may either worsen inflammatory responses and viral persistence or support adaptive mechanisms that reduce cellular damage. The potential for targeting HIF-1α therapeutically in COVID-19 is complex, requiring further investigation to clarify its precise role and translational applications. This review deepens the molecular understanding of SARS-CoV-2-induced cellular and tissue dysfunction in hypoxia, offering insights for improving clinical management strategies and addressing long-term sequelae.
dc.description.issuenumber9
dc.description.volume26
dc.identifier.doi10.3390/ijms26094202
dc.identifier.issnNone
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/40888
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.rightsAcesso Restrito
dc.subject.otherlanguageHIF-1α
dc.subject.otherlanguagehypoxia
dc.subject.otherlanguageinflammation
dc.subject.otherlanguagepost-acute COVID-19 syndrome
dc.subject.otherlanguageSARS-CoV-2
dc.titleHIF-1α Pathway in COVID-19: A Scoping Review of Its Modulation and Related Treatments
dc.typeArtigo de revisão
local.scopus.citations0
local.scopus.eid2-s2.0-105004885448
local.scopus.subjectCoronavirus Infections
local.scopus.subjectCOVID-19
local.scopus.subjectCOVID-19 Drug Treatment
local.scopus.subjectHumans
local.scopus.subjectHypoxia-Inducible Factor 1, alpha Subunit
local.scopus.subjectInflammation
local.scopus.subjectPandemics
local.scopus.subjectSARS-CoV-2
local.scopus.subjectSignal Transduction
local.scopus.updated2025-07-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105004885448&origin=inward
Arquivos
Coleções
Artigos de periódico